US › Healthcare

Grifols SA ADR (GRFS)

US · Healthcare · Drug Manufacturers - General

$8.07+2.67%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$1.87B
Revenue YoY
-0.9%
Net profit
$154.0M
Profit YoY
+31.6%
EPS
$0.19
EPS estimate
$0.28
Net margin
8.2%

EPS came in at 0.19 against a street estimate of 0.28 — a miss of 32.1%.

Key statistics

Market cap
$5.35B
P/E
10.3
Forward P/E
8.7
P/B
0.84
Book value
$4.57
EPS (TTM)
$0.76
Dividend yield
3.57%
52-week high
$10.70
52-week low
$6.87
50-day MA
$7.54
200-day MA
$8.44
Beta
1.19

Analyst view

Analysts rate Grifols SA ADR a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $10.87.

Shareholding

Institutions
58.30%

Largest institutional holders

FundStake
Brandes Investment Partners & Co5.34%
Capital World Investors3.37%
Permian Investment Partners2.84%
Black Creek Investment Management Inc1.23%
Millennium Management LLC0.74%
Bank of America Corp0.64%
HHG PLC0.48%
UBS Group AG0.46%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Grifols SA ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.